Early-Life Gut Health and Microbiota Development with Bifidobacterium infantis M-63

Bifidobacterium infantis M-63 has emerged as a clinically supported probiotic strain for early-life nutrition,particularly in the context of gut microbiota development. Increasing scientific attention has been placed on the importance of establishing a healthy gut microbiome during infancy, as it plays a key role in immune development and long-term health.

B. infantis M-63 is a human-residential bifidobacterium (HRB) originally isolated from infants and is well adopted to the early-life gut environment. Its ability to utilize human milk oligosaccharides (HMOs) and promote the growth of beneficial bifidobacteria makes it a valuable solution for infant nutrition.

· B. infantis M-63 supports the establishment of a bifidobacteria-dominant gut microbiota during early life.

·   The strain efficiently utilizes HMOs, key nutrients that selectively promote beneficial bacteria in breastfed infants.

·   Clinical studies demonstrate increased bifidobacteria abundance and improved gut environment markets following M-63 supplementation.

·   M-63 is supported by a strong safety and regulatory profile, including FDA GRAS status and global certifications

Understanding the Unique Properties

B. infantis M-63 is widely recognized for its role in shaping the infant gut microbiome during the critical early postnatal period. As a human-residential bifidobacterium, it is naturally adapted to colonize the infant gut and interact with key nutritional components such as HMOs.

Rather than focusing on a single functional outcome, the value of M-63 lies in its ability to support the natural development of the gut microbiota ecosystem, which is closely linked to immune maturation and overall infant health.

How the Strain Supports Microbiota

B. infantis M-63 supports early-life microbiota development through its strong ability to utilize a variety of types of human milk oligosaccharides. These complex carbohydrates, abundant in breast milk, are not digested by the infant but instead serve as a selective energy source for beneficial bacteria.

B. infantis M-63 works to enhance the microbiota composition by elevating bifidobacterium abundance, an outcome consistently noted in Morinaga’s latest published study highlights the efficacy of the strain in optimizing the infant microbiome compared to other probiotic species. What sets it apart is not merely the ability to deliver viable bacteria, but its targeted functionality rooted in the species’ natural adaptation to the infant gut.

In a randomized, placebo-controlled clinical study, supplementation with M-63 significantly increased the relative abundance of bifidobacteria from as early as one week after birth. This effect was sustained over time, supporting the establishment of a bifidobacteria-rich gut environment.

Importantly, M-63 demonstrated benefits even under conditions where bifidobacteria colonization is typically reduced, such as cesarean delivery or maternal antibiotic exposure. In these cases, supplementation helped promote microbiota development toward a profile more similar to that of breastfed infants.

The benefits of B. infantis M-63 are closely linked to its impact on the gut environment and microbiota composition. By promoting bifidobacteria colonization, M-63 contributes to the production of beneficial metabolites such as short-chain fatty acids, including acetic acid.

Clinical findings also indicate improvements in gut environment markers, including lower stool pH, increased IgA levels, and improved stool frequency and consistency. These changes are associated with a healthier intestinal environment and support the natural development of the infant gut.

Key Property	Benefit for Infants	Our Contributions	Innovation/Distinction
Human Origin	Better colonization of the infant gut	Isolation and selection of M-63 strain	Focus on strains native to infants
Efficient HMO Utilization	Supports healthy gut microbiota balance	Demonstrated superior HMO metabolism	Aligns probiotic function with breastfed infants’ needs
Safety and Tolerability	Reduced risk of adverse reactions	In-depth research and clinical validation	Stringent quality and safety standards
Immune System Support	Establish an early immune development	Studies showing enhanced immune markers	Integrated health benefits beyond digestion Support a healthy foundation for lifelong health for the infant/child.

This table provides a concise overview of the distinct benefits associated with  B. infantis M-63 in early-life probiotic supplementation.

Regulatory Excellence and Scientific Credibility

Probiotic strain B. infantis M-63 is supported by a strong safety and regulatory profile, making it suitable for use in infant nutrition.

• FDA GRAS (2022) for infant formula and foods
• China New Food Raw Material approval (2024)
• Produced under FSSC 22000, Halal, and Kosher certifications
• Supported by more than 36 scientific studies

These credentials provide confidence for companies seeking globally compliant, science-based probiotic solutions.

Partnering for Success: Next Steps for B2B Collaboration on Probiotic Innovation

At Morinaga, we support our partners with clinically validated probiotic solutions for early-life nutrition. B. infantis M-63 offers a strong scientific foundation, regulatory readiness, and application flexibility across infant formula and functional food formats.

Our experience enables partners to develop products that align with evolving consumer demand for science-backed, microbiome-focused nutrition.

For more on the science behind B. infantis M-63 and its applications, please contact us today. This partnership approach helps companies differentiate in the expanding market for infant and early childhood probiotics with credible, evidence-backed solutions.

Morinaga Nutritional Foods, a probiotic manufacturer leader in the development and clinical application of human-residential bifidobacterium adapted to the infant gut and closely associated with breast milk. These characteristics provide opportunities to support early-life gut microbiota development and related physiological functions.

We welcome discussions on how Morinaga’s probiotics, including the flagship strain, B. longum BB536, can complement your product portfolio. Read more –In-depth resource on BB536. Our global experience and technical support can help accelerate product development while ensuring regulatory compliance and consistent quality.

Bifidobacterium infantis M-63 is a clinically supported probiotic designed to promote early-life gut microbiota development. Through its strong HMO utilization and ability to support bifidobacteria colonization—even under challenging conditions such as cesarean delivery or antibiotic exposure—M-63 provides a practical and science-based solution for infant nutrition.

Combined with a robust regulatory profile and extensive research background, M-63 represents a reliable ingredient for next-generation early-life health products.